TY - JOUR AU - O'Quigley, J. AU - Pepe, M. AU - Fisher, J. PY - 1990 DA - 1990// TI - Continual reassessment method: a practical design for phase I clinical trials in cancer JO - Biometrics VL - 46 UR - https://doi.org/10.2307/2531628 DO - 10.2307/2531628 ID - O'Quigley1990 ER - TY - JOUR AU - Storer, B. E. PY - 1989 DA - 1989// TI - Design and analysis of phase 1 clinical trials in cancer JO - Biometrics VL - 45 UR - https://doi.org/10.2307/2531693 DO - 10.2307/2531693 ID - Storer1989 ER - TY - JOUR AU - Reiner, E. AU - Paoletti, X. AU - O'Quigley, J. PY - 1999 DA - 1999// TI - Operating characteristics of the standard phase I clinical trial design JO - Comput Stat Data Anal VL - 30 UR - https://doi.org/10.1016/S0167-9473(98)00095-4 DO - 10.1016/S0167-9473(98)00095-4 ID - Reiner1999 ER - TY - JOUR AU - Iasonos, A. AU - Wilton, A. S. AU - Riedel, E. R. PY - 2008 DA - 2008// TI - A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in phase I dose-finding studies JO - Clin Trials VL - 5 UR - https://doi.org/10.1177/1740774508096474 DO - 10.1177/1740774508096474 ID - Iasonos2008 ER - TY - JOUR AU - Iasonos, A. AU - O'Quigley, J. PY - 2014 DA - 2014// TI - Adaptive dose-finding studies: a review of model-guided phase I clinical trials JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.54.6051 DO - 10.1200/JCO.2013.54.6051 ID - Iasonos2014 ER - TY - JOUR AU - Le Tourneau, C. AU - Lee, J. J. AU - Siu, L. L. PY - 2009 DA - 2009// TI - Dose escalation methods in phase I clinical trials JO - J Natl Cancer Inst VL - 101 UR - https://doi.org/10.1093/jnci/djp079 DO - 10.1093/jnci/djp079 ID - Le Tourneau2009 ER - TY - JOUR AU - Paoletti, X. AU - Ezzalfani, M. AU - Le Tourneau, C. PY - 2015 DA - 2015// TI - Statistical controversies in clinical research: requiem for the 3+3 design for phase I trials JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv266 DO - 10.1093/annonc/mdv266 ID - Paoletti2015 ER - TY - JOUR AU - Nie, L. AU - Rubin, E. H. AU - Mehrotra, N. PY - 2016 DA - 2016// TI - Rendering the 3+3 design to rest: more efficient approaches to oncology dose-finding trials in the era of targeted therapy JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2644 DO - 10.1158/1078-0432.CCR-15-2644 ID - Nie2016 ER - TY - BOOK AU - Cheung, Y. K. PY - 2011 DA - 2011// TI - Dose-finding by the continual reassessment method PB - Chapman and Hall/CRC Press CY - New York UR - https://doi.org/10.1201/b10783 DO - 10.1201/b10783 ID - Cheung2011 ER - TY - JOUR AU - Paoletti, X. AU - Kramar, A. PY - 2009 DA - 2009// TI - A comparison of model choices for the continual reassessment method in phase I clinical trials JO - Stat Med VL - 28 UR - https://doi.org/10.1002/sim.3682 DO - 10.1002/sim.3682 ID - Paoletti2009 ER - TY - JOUR AU - Iasonos, A. AU - Wages, N. A. AU - Conaway, M. R. AU - Cheung, Y. K. AU - Yuan, Y. AU - O'Quigley, J. PY - 2016 DA - 2016// TI - Dimension of model parameter space and operating characteristics in adaptive dose-finding studies JO - Stat Med VL - 35 UR - https://doi.org/10.1002/sim.6966 DO - 10.1002/sim.6966 ID - Iasonos2016 ER - TY - JOUR AU - Lee, S. M. AU - Cheung, Y. K. PY - 2009 DA - 2009// TI - Model calibration in the continual reassessment method JO - Clinical Trials VL - 6 UR - https://doi.org/10.1177/1740774509105076 DO - 10.1177/1740774509105076 ID - Lee2009 ER - TY - JOUR AU - O'Quigley, J. AU - Zohar, S. PY - 2010 DA - 2010// TI - Retrospective robustness of the continual reassessment method JO - J Biopharm Stat VL - 20 UR - https://doi.org/10.1080/10543400903315732 DO - 10.1080/10543400903315732 ID - O'Quigley2010 ER - TY - JOUR AU - Pan, H. AU - Yuan, Y. PY - 2017 DA - 2017// TI - A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials JO - Stat Med VL - 36 UR - https://doi.org/10.1002/sim.6941 DO - 10.1002/sim.6941 ID - Pan2017 ER - TY - JOUR AU - Lee, S. M. AU - Cheung, Y. K. PY - 2011 DA - 2011// TI - Calibration of prior variance in the Bayesian continual reassessment method JO - Stat Med VL - 30 UR - https://doi.org/10.1002/sim.4139 DO - 10.1002/sim.4139 ID - Lee2011 ER - TY - JOUR AU - O’Quigley, J. AU - Shen, L. Z. PY - 1996 DA - 1996// TI - Continual reassessment method: a likelihood approach JO - Biometrics VL - 52 UR - https://doi.org/10.2307/2532905 DO - 10.2307/2532905 ID - O’Quigley1996 ER - TY - JOUR AU - Natarajan, L. AU - O’Quigley, J. PY - 2003 DA - 2003// TI - Interval estimates of the probability of toxicity at the maximum tolerated dose for small samples JO - Stat Med VL - 22 UR - https://doi.org/10.1002/sim.1443 DO - 10.1002/sim.1443 ID - Natarajan2003 ER - TY - STD TI - R Core Team. R: a language and environment for statistical computing; 2014. Available from: http://www.r-project.org. UR - http://www.r-project.org ID - ref18 ER - TY - STD TI - Chang W, Cheng J, Allaire J, Xie Y, McPherson J. shiny: Web Application Framework for R; Available from: http://cran.r-project.org/package=shiny; 2015. UR - http://cran.r-project.org/package=shiny ID - ref19 ER - TY - JOUR AU - Iasonos, A. AU - Gönen, M. AU - Bosl, G. J. PY - 2015 DA - 2015// TI - Scientific review of phase I protocols with novel dose escalation designs: how much information is needed JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.8466 DO - 10.1200/JCO.2014.59.8466 ID - Iasonos2015 ER - TY - JOUR AU - Petroni, G. R. AU - Wages, N. A. AU - Paux, G. AU - Dubois, F. PY - 2017 DA - 2017// TI - Implementation of adaptive methods in early-phase clinical trials JO - Stat Med VL - 36 UR - https://doi.org/10.1002/sim.6910 DO - 10.1002/sim.6910 ID - Petroni2017 ER - TY - JOUR AU - Wheeler, G. M. AU - Sweeting, M. J. AU - Mander, A. P. PY - 2016 DA - 2016// TI - AplusB: a web application for investigating a + B designs for phase I cancer clinical trials JO - PLoS One VL - 11 UR - https://doi.org/10.1371/journal.pone.0159026 DO - 10.1371/journal.pone.0159026 ID - Wheeler2016 ER - TY - STD TI - Wages NA, Varhegyi N. A web application for evaluating phase I methods using a non-parametric optimal benchmark. Clinical Trials. 2017;14:553-57. ID - ref23 ER -